Alexandra Blenkinsop1,2, Mélodie Monod1, Ard van Sighem3, Nikos Pantazis4, Daniela Bezemer3, Eline Op de Coul5, Thijs van de Laar6,7, Christophe Fraser8, Maria Prins9, Peter Reiss2,10, Godelieve J de Bree2,11, Oliver Ratmann1. 1. Department of Mathematics, Imperial College London, London, United Kingdom. 2. Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands. 3. Stichting HIV Monitoring, Amsterdam, Netherlands. 4. Department of Hygiene, Epidemiology and Medical Statistics, University of Athens, Athens, Greece. 5. Center for Infectious Diseases Prevention and Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands. 6. Department of Donor Medicine Research, Sanquin, Amsterdam, Netherlands. 7. Department of Medical Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands. 8. Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom. 9. Academic Medical Center, Amsterdam, Netherlands. 10. Department of Global Health, Amsterdam University Medical Centers, Amsterdam, Netherlands. 11. Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Infection and Immunity Institute, Amsterdam, Netherlands.
Abstract
Background: More than 300 cities including the city of Amsterdam in the Netherlands have joined the UNAIDS Fast-Track Cities initiative, committing to accelerate their HIV response and end the AIDS epidemic in cities by 2030. To support this commitment, we aimed to estimate the number and proportion of Amsterdam HIV infections that originated within the city, from Amsterdam residents. We also aimed to estimate the proportion of recent HIV infections during the 5-year period 2014-2018 in Amsterdam that remained undiagnosed. Methods: We located diagnosed HIV infections in Amsterdam using postcode data (PC4) at time of registration in the ATHENA observational HIV cohort, and used HIV sequence data to reconstruct phylogeographically distinct, partially observed Amsterdam transmission chains. Individual-level infection times were estimated from biomarker data, and used to date the phylogenetically observed transmission chains as well as to estimate undiagnosed proportions among recent infections. A Bayesian Negative Binomial branching process model was used to estimate the number, size, and growth of the unobserved Amsterdam transmission chains from the partially observed phylogenetic data. Results: Between 1 January 2014 and 1 May 2019, there were 846 HIV diagnoses in Amsterdam residents, of whom 516 (61%) were estimated to have been infected in 2014-2018. The rate of new Amsterdam diagnoses since 2014 (104 per 100,000) remained higher than the national rates excluding Amsterdam (24 per 100,000), and in this sense Amsterdam remained a HIV hotspot in the Netherlands. An estimated 14% [12-16%] of infections in Amsterdan MSM in 2014-2018 remained undiagnosed by 1 May 2019, and 41% [35-48%] in Amsterdam heterosexuals, with variation by region of birth. An estimated 67% [60-74%] of Amsterdam MSM infections in 2014-2018 had an Amsterdam resident as source, and 56% [41-70%] in Amsterdam heterosexuals, with heterogeneity by region of birth. Of the locally acquired infections, an estimated 43% [37-49%] were in foreign-born MSM, 41% [35-47%] in Dutch-born MSM, 10% [6-18%] in foreign-born heterosexuals, and 5% [2-9%] in Dutch-born heterosexuals. We estimate the majority of Amsterdam MSM infections in 2014-2018 originated in transmission chains that pre-existed by 2014. Conclusions: This combined phylogenetic, epidemiologic, and modelling analysis in the UNAIDS Fast-Track City Amsterdam indicates that there remains considerable potential to prevent HIV infections among Amsterdam residents through city-level interventions. The burden of locally acquired infection remains concentrated in MSM, and both Dutch-born and foreign-born MSM would likely benefit most from intensified city-level interventions. Funding: This study received funding as part of the H-TEAM initiative from Aidsfonds (project number P29701). The H-TEAM initiative is being supported by Aidsfonds (grant number: 2013169, P29701, P60803), Stichting Amsterdam Dinner Foundation, Bristol-Myers Squibb International Corp. (study number: AI424-541), Gilead Sciences Europe Ltd (grant number: PA-HIV-PREP-16-0024), Gilead Sciences (protocol numbers: CO-NL-276-4222, CO-US-276-1712, CO-NL-985-6195), and M.A.C AIDS Fund.
Background: More than 300 cities including the city of Amsterdam in the Netherlands have joined the UNAIDS Fast-Track Cities initiative, committing to accelerate their HIV response and end the AIDS epidemic in cities by 2030. To support this commitment, we aimed to estimate the number and proportion of Amsterdam HIV infections that originated within the city, from Amsterdam residents. We also aimed to estimate the proportion of recent HIV infections during the 5-year period 2014-2018 in Amsterdam that remained undiagnosed. Methods: We located diagnosed HIV infections in Amsterdam using postcode data (PC4) at time of registration in the ATHENA observational HIV cohort, and used HIV sequence data to reconstruct phylogeographically distinct, partially observed Amsterdam transmission chains. Individual-level infection times were estimated from biomarker data, and used to date the phylogenetically observed transmission chains as well as to estimate undiagnosed proportions among recent infections. A Bayesian Negative Binomial branching process model was used to estimate the number, size, and growth of the unobserved Amsterdam transmission chains from the partially observed phylogenetic data. Results: Between 1 January 2014 and 1 May 2019, there were 846 HIV diagnoses in Amsterdam residents, of whom 516 (61%) were estimated to have been infected in 2014-2018. The rate of new Amsterdam diagnoses since 2014 (104 per 100,000) remained higher than the national rates excluding Amsterdam (24 per 100,000), and in this sense Amsterdam remained a HIV hotspot in the Netherlands. An estimated 14% [12-16%] of infections in Amsterdan MSM in 2014-2018 remained undiagnosed by 1 May 2019, and 41% [35-48%] in Amsterdam heterosexuals, with variation by region of birth. An estimated 67% [60-74%] of Amsterdam MSM infections in 2014-2018 had an Amsterdam resident as source, and 56% [41-70%] in Amsterdam heterosexuals, with heterogeneity by region of birth. Of the locally acquired infections, an estimated 43% [37-49%] were in foreign-born MSM, 41% [35-47%] in Dutch-born MSM, 10% [6-18%] in foreign-born heterosexuals, and 5% [2-9%] in Dutch-born heterosexuals. We estimate the majority of Amsterdam MSM infections in 2014-2018 originated in transmission chains that pre-existed by 2014. Conclusions: This combined phylogenetic, epidemiologic, and modelling analysis in the UNAIDS Fast-Track City Amsterdam indicates that there remains considerable potential to prevent HIV infections among Amsterdam residents through city-level interventions. The burden of locally acquired infection remains concentrated in MSM, and both Dutch-born and foreign-born MSM would likely benefit most from intensified city-level interventions. Funding: This study received funding as part of the H-TEAM initiative from Aidsfonds (project number P29701). The H-TEAM initiative is being supported by Aidsfonds (grant number: 2013169, P29701, P60803), Stichting Amsterdam Dinner Foundation, Bristol-Myers Squibb International Corp. (study number: AI424-541), Gilead Sciences Europe Ltd (grant number: PA-HIV-PREP-16-0024), Gilead Sciences (protocol numbers: CO-NL-276-4222, CO-US-276-1712, CO-NL-985-6195), and M.A.C AIDS Fund.
Authors: Elske Hoornenborg; Liza Coyer; Roel C A Achterbergh; Amy Matser; Maarten F Schim van der Loeff; Anders Boyd; Yvonne T H P van Duijnhoven; Sylvia Bruisten; Paul Oostvogel; Udi Davidovich; Arjan Hogewoning; Maria Prins; Henry J C de Vries Journal: Lancet HIV Date: 2019-06-06 Impact factor: 12.767
Authors: Nikos Pantazis; Christos Thomadakis; Julia Del Amo; Debora Alvarez-Del Arco; Fiona M Burns; Ibidun Fakoya; Giota Touloumi Journal: Stat Methods Med Res Date: 2017-12-12 Impact factor: 3.021
Authors: R L J Heijman; I G Stolte; H F J Thiesbrummel; E van Leent; R A Coutinho; J S A Fennema; M Prins Journal: Sex Transm Infect Date: 2008-12-22 Impact factor: 3.519
Authors: Eline L M Op de Coul; Ard van Sighem; Kees Brinkman; Birgit H van Benthem; Marchina E van der Ende; Suzanne Geerlings; Peter Reiss Journal: BMJ Open Date: 2016-01-04 Impact factor: 2.692
Authors: Chris Wymant; Matthew Hall; Oliver Ratmann; David Bonsall; Tanya Golubchik; Mariateresa de Cesare; Astrid Gall; Marion Cornelissen; Christophe Fraser Journal: Mol Biol Evol Date: 2018-03-01 Impact factor: 16.240
Authors: Ann M Dennis; Simon D W Frost; Kimberly Enders; Andrew E Cressman; Erik Volz; Nicole Adams; William C Miller; Myron S Cohen; Victoria Mobley; Erika Samoff; Joseph J Eron Journal: EClinicalMedicine Date: 2021-06-17
Authors: M Bartelsman; I K Joore; J E van Bergen; A A Hogewoning; F R Zuure; M G van Veen Journal: BMC Infect Dis Date: 2017-08-01 Impact factor: 3.090